Rigel Pharmaceuticals, Inc. (RIGL) belonging to the Healthcare sector has declined -9.3% and closed its last trading session at $3.22.
The company reported its EPS on 3/30/2018. Currently, the stock has a 1 Year Price Target of $7.92.
The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 1 respectively.
Rigel Pharmaceuticals, Inc. on 3/30/2018 reported its EPS as $-0.16 with the analysts projecting the EPS of the stock as $-0.15. The company beat the analyst EPS Estimate with the difference of $-0.01. This shows a surprise factor of -0.067%.
Many analysts have provided their estimated foresights on Rigel Pharmaceuticals, Inc. Earnings, with 6 analysts believing the company would generate an Average Estimate of $-0.16.
Whereas they predicted High and Low Earnings Estimate as $-0.16 and $-0.17 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.16.
Analysts are also projecting an Average Revenue Estimate for Rigel Pharmaceuticals, Inc. as $180000 in the Current Quarter. This estimate is provided by 6 analysts.
Rigel Pharmaceuticals, Inc. (RIGL) has the market capitalization of $562.37 Million. The company rocked its 52-Week High of $4.71 and touched its 52-Week Low of $2.14.
The stock has Return on Assets (ROA) of -93 percent. Return on Equity (ROE) stands at -113.7% and Return on Investment (ROI) of -79.1 percent.
The stock is currently showing YTD performance of -17.01 Percent. The company has Beta Value of 1.24 and ATR value of 0.22. The Weekly and Monthly Volatility stands at 8.24% and 5.75%.